mTOR is the major regulator of growth in animals. mTOR is activated by oxidative stress, which humans aim to avoid. Therefore, drugs that target mTOR inhibition may delay the aging process.
My below thoughts are based on Rapamycin and it's rapalogs. There is a paucity of information on Monepantel to correctly hypothesize it's attributes, but I believe they are close.
Monepantel has been found to inhibit the mTOR signaling pathway, which is controlled by the mammalian target of rapamycin (mTOR), and is understood to exert similar anticancer activity as rapamycin.
A study suggests that monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer, similar to the effects of rapamycin and mTOR inhibitors in cancer treatment.
Additionally, monepantel induces autophagy in human ovarian cancer cells through the disruption of the mTOR/p70S6K signaling pathway, similar to the effects of rapamycin.
Both drugs have been studied for their potential anticancer effects, with Monepantel showing promise in enhancing the therapeutic potential of other cancer treatment drugs.
Additionally, both drugs have been found to induce autophagy in cancer cells through disruption of the mTOR/p70S6K signaling pathwayHowever, it's important to note that Monepantel has a different chemical structure than Rapamycin and is reported to have an apparently better safety profile.
It is interesting that a longitudinal study " The test of Rapamycin in ageing dogs (Triad 2023) has started being a ten year, 10000 dog study.
In Selvarini et al 2021 study " Effects of Rapamycin on ageing related diseases, past and future" came to these conclusions.
Reduced aortic atheroma Reduced cardiomyopathy Reduced cardiac fibrosis Reduced tau pathology ( see below reference 3) Restores cerebral blood flow Reduced neuro inflammation Reduced Amyloid protein levels Prevents loss of (TH+) neurones ( see below reference number 1) Increased various measured muscle coordination Enhanced clearance of Poly Q aggregates ( see below reference number 2) Lithium and Rapamycin may affect neurogeneration in Huntingtons disease Reduced anxiety like behaviour Reduced depression Increases vaccine efficacy increasing anti bodies Reduced cellular cerebral senescence
Barnett et al 2023 in their study " A masked placebo controlled randomised clinical trial evaluating safety of the effect of long dose Rapamycin in 17 healthy client owned dogs" state:
26.8% a positive correlation in perceived changes in behaviour in dogs Alters mRNA translation Induced macroautophagy Improves stem cell function Reduced systolic blood pressure No QT abnormalities No troponin changes
In relation to mice Barnett et al states:
Increased lifespan in mice. Males by 45%. Females by 45% at a dosage of 126 PPM. Improved cognitive and muscle function Reduced tumorigenesis Prevention of retinopathy Restoration of stem cell function Reversal immune declines Reversal periodontal disease Improved kidney function Improved intestinal function Reduced gut dysbiosis Preservation of ovarian function Protection against hearing loss Improving systolic ejection fractionDecreasing cardiomyopathy
Of course there may be adverse event sequel. Including hyperlipidemia/ gonad hypertrophy/ cataract formations/ altered glucose homeostasis/ crossover over long term usage on mTORC1.
The goal of Monepantel treatment is to prevent particular life-limiting age-related diseases that would kill a particular person. In relation to usage on healthcare on healthy clients it needs more clinical measurements but in saying that it is a near perfect candidate due to its safety profile to confidently say it deserves more investigation.
Ref : Pattern of Tyrosine hydroxylase expression on ageing of mesolimbic pathway of the rat. 2018
Ref : Inplanta expression of human PolyQ expanded Huntington's fragments reveal mechanism to prevent disease related protein aggregation. 2023
Ref : Tau pathology mediated age effects on medial temporal lobe structure. 2022
(20min delay)